Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 1-2/2017

01.02.2017 | main topic

Diagnosis and treatment of Paget’s disease of bone

A clinical practice guideline

verfasst von: Christian Muschitz, MD, Xaver Feichtinger, Judith Haschka, Roland Kocijan

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 1-2/2017

Einloggen, um Zugang zu erhalten

Summary

Paget’s disease of bone (osteitis deformans) is a benign focal disorder of accelerated skeletal remodeling. Either a single bone (monostotic) or multiple bones (polyostotic) can be affected. In patients with suspected Paget’s disease plain radiographs of the suspicious regions of the skeleton are recommended. The initial biochemical evaluation of a patient should be done using serum total ALP (alkaline phosphatase) or with the use of a more specific marker of bone formation: PINP (intact N-terminal type 1 procollagen propeptide) or CTX (cross-linked C‑telopeptide). Treatment with a bisphosphonate is recommended for most patients with active Paget’s disease who are at risk for further skeletal and extraskeletal complications. A single dose of 5 mg i.v. zoledronate as the treatment of choice in patients without contraindications is suggested. Oral bisphosphonates are less potent when compared to zoledronate. Treatment with an antiresorptive agent induces a more rapid decrease in resorption markers compared to formation marker. Measurement of total ALP or other baseline disease activity markers (e. g. CTX) at 6 to 12 weeks, when bone turnover will have shown a substantial decline, is an acceptable and cost-effective option. Maximum suppression of high bone turnover may require measurement at 6 months after administration. In patients with increased bone turnover, biochemical follow-up is recommended to be used as a more objective indicator of relapse rather than symptoms. The prolonged response after zoledronate treatment should be assessed every 1–2 years after normal bone turnover. With less potent drugs, every 6 to 12 months is appropriate.
Literatur
1.
Zurück zum Zitat Ringe JD, Jend HH, Becker H. Epidemiologie der Osteitis deformans Paget. Munch Med Wschr. 1984;126:683–6. Ringe JD, Jend HH, Becker H. Epidemiologie der Osteitis deformans Paget. Munch Med Wschr. 1984;126:683–6.
2.
Zurück zum Zitat Mikosch P, Trifina E, Roschger P, Haller J, Klaushofer K. Klinik und Diagnose des Morbus Paget. J Mineralstoffwechsel Muskuloskelet Erkrank. 2012;19:68–73. Mikosch P, Trifina E, Roschger P, Haller J, Klaushofer K. Klinik und Diagnose des Morbus Paget. J Mineralstoffwechsel Muskuloskelet Erkrank. 2012;19:68–73.
3.
Zurück zum Zitat Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res. 2001;16:1379–87.CrossRefPubMed Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res. 2001;16:1379–87.CrossRefPubMed
4.
Zurück zum Zitat Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.CrossRefPubMed Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.CrossRefPubMed
5.
Zurück zum Zitat Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666–73.CrossRefPubMed Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666–73.CrossRefPubMed
6.
Zurück zum Zitat Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH, Reid IR, et al. Paget‘s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:4408–22.CrossRefPubMed Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH, Reid IR, et al. Paget‘s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:4408–22.CrossRefPubMed
7.
Zurück zum Zitat Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet. 2008;372:155–63.CrossRefPubMed Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet. 2008;372:155–63.CrossRefPubMed
8.
Zurück zum Zitat Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH. From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics. 2002;22:1191–216.CrossRefPubMed Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH. From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics. 2002;22:1191–216.CrossRefPubMed
10.
Zurück zum Zitat López C, Thomas DV, Davies AM. Neoplastic transformation and tumour-like lesions in Paget’s disease of bone: a pictorial review. Eur Radiol. 2003;13(Suppl 4):L151–63.CrossRefPubMed López C, Thomas DV, Davies AM. Neoplastic transformation and tumour-like lesions in Paget’s disease of bone: a pictorial review. Eur Radiol. 2003;13(Suppl 4):L151–63.CrossRefPubMed
11.
Zurück zum Zitat Shirazi PH, Ryan WG, Fordham EW. Bone scanning in evaluation of Paget’s disease of bone. CRC Crit Rev Clin Radiol Nucl Med. 1974;5:523–58.PubMed Shirazi PH, Ryan WG, Fordham EW. Bone scanning in evaluation of Paget’s disease of bone. CRC Crit Rev Clin Radiol Nucl Med. 1974;5:523–58.PubMed
12.
Zurück zum Zitat Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget’s disease. Eur J Nucl Med. 1980;5:417–21.PubMed Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget’s disease. Eur J Nucl Med. 1980;5:417–21.PubMed
13.
Zurück zum Zitat Eekhoff MEMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE. Determinants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate) therapy. Bone. 2003;33:831–8.CrossRefPubMed Eekhoff MEMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE. Determinants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate) therapy. Bone. 2003;33:831–8.CrossRefPubMed
14.
Zurück zum Zitat Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum. 1997;40:461–8.CrossRefPubMed Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum. 1997;40:461–8.CrossRefPubMed
15.
Zurück zum Zitat Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem. 1995;41:1592–8.PubMed Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem. 1995;41:1592–8.PubMed
16.
Zurück zum Zitat Withold W, Schulte U, Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem. 1996;42:210–7.PubMed Withold W, Schulte U, Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem. 1996;42:210–7.PubMed
17.
Zurück zum Zitat Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res. 1995;10:458–65.CrossRefPubMed Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res. 1995;10:458–65.CrossRefPubMed
18.
Zurück zum Zitat Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget‘s disease. N Engl J Med. 2005;353:898–908.CrossRefPubMed Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget‘s disease. N Engl J Med. 2005;353:898–908.CrossRefPubMed
19.
Zurück zum Zitat Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235–42.PubMed Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235–42.PubMed
20.
Zurück zum Zitat Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.CrossRefPubMed Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.CrossRefPubMed
21.
Zurück zum Zitat Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142–8.CrossRefPubMed Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142–8.CrossRefPubMed
22.
Zurück zum Zitat Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011;26:2261–70.CrossRefPubMed Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011;26:2261–70.CrossRefPubMed
23.
Zurück zum Zitat Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380–7.CrossRefPubMed Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380–7.CrossRefPubMed
24.
Zurück zum Zitat Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032–8.CrossRefPubMed Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032–8.CrossRefPubMed
25.
Zurück zum Zitat Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22:51–5.CrossRefPubMed Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22:51–5.CrossRefPubMed
26.
Zurück zum Zitat Singer FR, Clemens TL, Eusebio RA, Bekker Risedronate PJ. A highly effective oral agent in the treatment of patients with severe Paget’s disease. J Clin Endocrinol Metab. 1998;83:1906–10.PubMed Singer FR, Clemens TL, Eusebio RA, Bekker Risedronate PJ. A highly effective oral agent in the treatment of patients with severe Paget’s disease. J Clin Endocrinol Metab. 1998;83:1906–10.PubMed
27.
Zurück zum Zitat Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone. 2004;35:224–30.CrossRefPubMed Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone. 2004;35:224–30.CrossRefPubMed
28.
Zurück zum Zitat Dodd GW, Ibbertson HK, Fraser TR, Holdaway IM, Wattie D. Radiological assessment of Paget’s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol. 1987;60:849–60.CrossRefPubMed Dodd GW, Ibbertson HK, Fraser TR, Holdaway IM, Wattie D. Radiological assessment of Paget’s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol. 1987;60:849–60.CrossRefPubMed
29.
Zurück zum Zitat Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab. 1996;81:961–7.PubMed Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab. 1996;81:961–7.PubMed
30.
Zurück zum Zitat Frijlink WB, Bijvoet OL, te Velde J, Heynen G. Treatment of Paget’s disease with (3-amino-1-hydroxypropylidene)-1, 1‑bisphosphonate (A.P.D.). Lancet. 1979;1:799–803.CrossRefPubMed Frijlink WB, Bijvoet OL, te Velde J, Heynen G. Treatment of Paget’s disease with (3-amino-1-hydroxypropylidene)-1, 1‑bisphosphonate (A.P.D.). Lancet. 1979;1:799–803.CrossRefPubMed
31.
Zurück zum Zitat Reid IR, Sharma S, Kalluru R, Eagleton C. Treatment of Paget’s disease of bone with denosumab: case report and literature review. Calcif Tissue Int. 2016; doi:10.1007/s00223-016-0150-6. Reid IR, Sharma S, Kalluru R, Eagleton C. Treatment of Paget’s disease of bone with denosumab: case report and literature review. Calcif Tissue Int. 2016; doi:10.​1007/​s00223-016-0150-6.
32.
Zurück zum Zitat Polyzos SA, Singhellakis PN, Naot D, Adamidou F, Malandrinou FC, Anastasilakis AD, et al. Denosumab treatment for juvenile Paget’s disease: results from two adult patients with osteoprotegerin deficiency (“Balkan” mutation in the TNFRSF11B gene). J Clin Endocrinol Metab. 2014;99:703–7.CrossRefPubMed Polyzos SA, Singhellakis PN, Naot D, Adamidou F, Malandrinou FC, Anastasilakis AD, et al. Denosumab treatment for juvenile Paget’s disease: results from two adult patients with osteoprotegerin deficiency (“Balkan” mutation in the TNFRSF11B gene). J Clin Endocrinol Metab. 2014;99:703–7.CrossRefPubMed
33.
Zurück zum Zitat Grasemann C, Schündeln MM, Hövel M, Schweiger B, Bergmann C, Herrmann R, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab. 2013;98:3121–6.CrossRefPubMed Grasemann C, Schündeln MM, Hövel M, Schweiger B, Bergmann C, Herrmann R, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab. 2013;98:3121–6.CrossRefPubMed
34.
Zurück zum Zitat Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617–27.CrossRefPubMed Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617–27.CrossRefPubMed
35.
Zurück zum Zitat Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med. 1995;155:1813–5.CrossRefPubMed Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med. 1995;155:1813–5.CrossRefPubMed
36.
Zurück zum Zitat Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget’s disease of bone. J Bone Miner Res. 1993;8:1467–73.CrossRefPubMed Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget’s disease of bone. J Bone Miner Res. 1993;8:1467–73.CrossRefPubMed
37.
Zurück zum Zitat el Sammaa M, Linthicum FH, House HP, House JW. Calcitonin as treatment for hearing loss in Paget’s disease. Am J Otol. 1986;7:241–3.PubMed el Sammaa M, Linthicum FH, House HP, House JW. Calcitonin as treatment for hearing loss in Paget’s disease. Am J Otol. 1986;7:241–3.PubMed
38.
Zurück zum Zitat Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg. 2002;10:409–16.CrossRefPubMed Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg. 2002;10:409–16.CrossRefPubMed
40.
Zurück zum Zitat Meyers MH, Singer FR. Osteotomy for tibia vara in Paget’s disease under cover of calcitonin. J Bone Joint Surg Am. 1978;60:810–4.CrossRefPubMed Meyers MH, Singer FR. Osteotomy for tibia vara in Paget’s disease under cover of calcitonin. J Bone Joint Surg Am. 1978;60:810–4.CrossRefPubMed
41.
Zurück zum Zitat Chen JR, Rhee RS, Wallach S, Avramides A, Flores A. Neurologic disturbances in Paget disease of bone: response to calcitonin. Neurology. 1979;29:448–57.CrossRefPubMed Chen JR, Rhee RS, Wallach S, Avramides A, Flores A. Neurologic disturbances in Paget disease of bone: response to calcitonin. Neurology. 1979;29:448–57.CrossRefPubMed
42.
Zurück zum Zitat Chawla S, Henshaw R, Seeger L, Choy E, Blay J‑Y, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901–8.CrossRefPubMed Chawla S, Henshaw R, Seeger L, Choy E, Blay J‑Y, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901–8.CrossRefPubMed
43.
Zurück zum Zitat van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res. 2002;17:465–71.CrossRefPubMed van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res. 2002;17:465–71.CrossRefPubMed
Metadaten
Titel
Diagnosis and treatment of Paget’s disease of bone
A clinical practice guideline
verfasst von
Christian Muschitz, MD
Xaver Feichtinger
Judith Haschka
Roland Kocijan
Publikationsdatum
01.02.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 1-2/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0502-x

Weitere Artikel der Ausgabe 1-2/2017

Wiener Medizinische Wochenschrift 1-2/2017 Zur Ausgabe